RT Journal Article
SR Electronic
T1 Tumor MHC-II Neoantigens Maintain CD8+ T-cell Antitumor Immunity
JF Cancer Discovery
JO Cancer Discov
FD American Association for Cancer Research
DO 10.1158/2159-8290.CD-RW2019-166
YR 2019
UL http://cancerdiscovery.aacrjournals.org/content/early/2019/11/01/2159-8290.CD-RW2019-166.abstract
AB MHC class II restricted neoantigens play a critical role in response to immune checkpoint therapy (ICT).